C-Kit (CD117) Expression in Patients with Small Cell Lung Cancer
PDF
Cite
Share
Request
Original Article
P: 67-71
March 2015

C-Kit (CD117) Expression in Patients with Small Cell Lung Cancer

Med Bull Haseki 2015;53(1):67-71
1. Uludağ Üniversitesi Tıp Fakültesi, İç Hastalıkları Anabilim Dalı, Bursa, Türkiye
2. Uludağ Üniversitesi Tıp Fakültesi, İç Hastalıkları Anabilim Dalı, Onkoloji Bilim Dalı, Bursa, Türkiye
3. Bakırköy Dr. Sadi Konuk Hastanesi, İç Hastalıkları Kliniği, Onkoloji Bölümü, İstanbul, Türkiye
4. Uludağ Üniversitesi Tıp Fakültesi, Patoloji Anabilim Dalı, Bursa, Türkiye
5. Bakırköy Dr. Sadi Konuk Hastanesi, İç Hastalıkları Kliniği, İstanbul, Türkiye
No information available.
No information available
Received Date: 20.08.2014
Accepted Date: 10.09.2014
PDF
Cite
Share
Request

ABSTRACT

Conclusion:

New prognostic markers and more effective treatment regimens are needed for SCLC. Our findings may provide an insight to future clinical trials searching c-kit inhibitors in SCLC.

Results:

The mean age of the patients was 57.1±9.9 years. Thirty-nine patients (44.8%) had limited disease and 48 patients (55.2%) had extensive disease. C-kit (+) expression was observed in 24.1% of 87 patients. The mean survival time for c-kit (+) patients was 10.2 (CI=5.7-14.7) months as compared with the c-kit (-) population in whom the survival was 14.7 (CI=10.7-18.6) months. The difference in survival time between c- kit (+) and (-) patients was not statistically significant (p=0.264).

Methods:

Demographic and clinical data of patients with SCLC was registered. C-kit overexpression was evaluated using immunohistochemistry performed in paraffin-embedded specimens. Immunostaining data of 87 patients were correlated with survival and other relevant clinical parameters.

Aim:

The tyrosine-kinase receptor c-kit and its ligand stem cell factor (SCF) are coexpressed in many small cell lung cancer (SCLC) cell lines. The aim of this study was to search the role of CD117 (c-kit) overexpression as a prognostic marker in SCLC.